Arkolith/Insider Trading/ALLO/Form 4

Douglas Earl Martin

SVP, General CounselAllogene Therapeutics, Inc. (ALLO) · full profile →Form 4 · filed Feb 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$40K
Net Open-Market Flow
-$40K
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2026Sell(S)23K$1.76$40K565K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 2, 2026Grant(A)152K—$0152K
Feb 2, 2026Grant(A)539K—$0539K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001362155-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML